Charles River Laboratories International (NYSE:CRL) Upgraded by Redburn Atlantic to "Neutral" Rating

Charles River Laboratories International (NYSE:CRL - Get Free Report) was upgraded by stock analysts at Redburn Atlantic from a "sell" rating to a "neutral" rating in a note issued to investors on Monday, MarketBeat.com reports. The firm presently has a $188.00 price target on the medical research company's stock. Redburn Atlantic's price objective would indicate a potential upside of 10.88% from the company's current price.

Several other research analysts have also commented on CRL. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. Evercore ISI raised their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Finally, CLSA downgraded Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $198.36.

Remove Ads

Charles River Laboratories International Stock Up 1.2 %

Shares of CRL stock traded up $2.00 during mid-day trading on Monday, hitting $169.55. The stock had a trading volume of 1,171,376 shares, compared to its average volume of 696,367. The firm has a market capitalization of $8.67 billion, a P/E ratio of 1,130.31, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International has a 12-month low of $150.79 and a 12-month high of $275.00. The firm's 50-day moving average is $169.69 and its two-hundred day moving average is $186.19.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the business posted $2.46 EPS. The company's quarterly revenue was down 1.1% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CRL. Empirical Finance LLC increased its holdings in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after buying an additional 53 shares in the last quarter. Fiduciary Financial Group LLC increased its holdings in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. M&T Bank Corp grew its holdings in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after buying an additional 66 shares during the last quarter. Finally, Cornerstone Investment Partners LLC increased its stake in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).